Study of 236 patients reveals utility of MolecuLight i:X® in detection and management of wound-related cellulitis

Published results describe use of point-of-care imaging for the early detection and proactive management of wound-related cellulitis

 

TORONTOOct. 12, 2021 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication in International Wound Journalof an independent prospective observational study examining the impact of incorporating fluorescence imaging into standard care for the diagnosis and management of wound-related cellulitis. Dr. Charles Andersen, a surgeon at the Madigan Army Medical Center, led this study on wound-related cellulitis, defined as an invasion of bacteria from chronic wounds into the adjacent dermis.

“The results of this study show how MolecuLight point-of-care imaging presents an intriguing solution to revealing extension of bacteria into tissue, reducing misdiagnosis of wound-associated cellulitis, and enabling more proactive early treatment, particularly in patients lacking obvious symptoms”, says Dr. Charles A. Andersen, Chief, Vascular/ Endovascular and Limb Preservation Surgery Service (Emeritus), Chief Wound Care Service and Medical Director Wound Care Clinic at Madigan Army Medical Center, Tacoma, WA. “Given that at least 30% of cellulitis cases are misdiagnosed,6,5 the addition of consistent and objective information provided by fluorescence scans can significantly reduce the uncertainty associated with diagnosis of wound-related cellulitis. In addition, the use of fluorescence imaging to support earlier detection and proactive management of wound-related cellulitis can limit progression of infection and avoid the need for intravenous antibiotics and the high costs associated with inpatient admission”.

An example case of wound-related cellulitis from the study is shown (above) where the wound does not appear to have cellulitis or elevated bacterial burden upon assessment with standard-of-care clinical signs and symptoms (left). In contrast, when imaged with the MolecuLight i:(right), an irregular pattern of red (bacterial) fluorescence extending beyond the wound bed and periwound is visible, and could not be removed with vigorous cleansing, indicating that the bacteria are located subsurface. This pattern of red fluorescence, demonstrating invasive extension of bacteria into surrounding tissues, was consistent in all wounds in the study where wound-related cellulitis was diagnosed.

Dr. Andersen will present the findings of this publication in a talk titled, “Diagnosis and Treatment of the Invasive Extension of Bacteria (Cellulitis) from Chronic Wounds Utilizing Point-of-Care Fluorescence Imaging at the upcoming clinical conference, SAWC (Symposium on Advanced Wound Care) Fall 2021 on Sunday, October 31, 2021 at 9:00 am at Caesars Palace in Las Vegas, Nevada.

References

1

Andersen, C.A. et al, “Diagnosis and Treatment of the Invasive Extension of Bacteria (Cellulitis) from Chronic Wounds Utilizing Point-of-Care Fluorescence Imaging“, International Wound Journal 2021: 1-13

2

Lazzarini L et al, J Infect. 2005;51(5):383-389.

3

Raff AB et al, JAMA. 2016;316(3): 325-337.

4

Pasternack MS. Mandell, Douglas, & Bennett’s Principles & Practice of Infectious Diseases. Vol 1; Phil., PA: Churchill Livingstone/Elsevier; 2010:1289-1312.

5

Weng QY et al, JAMA Dermatol. 2017;153(2):141-146.

6

Levell NJ et al, Br J Dermatol. 2011;164(6):1326-1328.

About MolecuLight Inc.

MolecuLight Inc., a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s first commercially released device, the MolecuLight i:X fluorescence imaging system and its accessories provide a point-of-care handheld imaging device for the global wound care market for the detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant, unmet needs including food safety, consumer cosmetics and other key industrial markets.

Image:
Download at: https://moleculight.box.com/s/oab22c1vi8ud1j8oymylbfogp2lg12bk

SOURCE MolecuLight

Related Links

www.moleculight.com

Newsletter Signup

Subscribe to our weekly newsletter below for an update of everything from the week